<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04761198</url>
  </required_header>
  <id_info>
    <org_study_id>MPH313-1-02</org_study_id>
    <secondary_id>2020-004222-37</secondary_id>
    <nct_id>NCT04761198</nct_id>
  </id_info>
  <brief_title>A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors.</brief_title>
  <official_title>A Phase 1b/2 Open-Label Study of the Efficacy and Safety of Etigilimab (MPH313) Administered in Combination With Nivolumab to Subjects With Locally Advanced or Metastatic Solid Tumors (ACTIVATE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mereo BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ICON Clinical Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mereo BioPharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, phase 1b/2, multicenter study designed to evaluate the efficacy,&#xD;
      safety, tolerability, PK, and pharmacodynamics of etigilimab in combination with nivolumab in&#xD;
      subjects with locally advanced or metastatic solid tumors. Subjects will be assigned to&#xD;
      receive etigilimab (every 2 weeks) in combination with nivolumab (240 mg every 2 weeks).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, phase 1b/2, multicenter study designed to evaluate the efficacy,&#xD;
      safety, tolerability, PK, and pharmacodynamics of etigilimab in combination with nivolumab in&#xD;
      subjects with locally advanced or metastatic solid tumors. Subjects will be assigned to&#xD;
      receive etigilimab (every 2 weeks) in combination with nivolumab (240 mg every 2 weeks) and&#xD;
      will continue until either unacceptable toxicity or disease progression. Subjects may&#xD;
      continue to receive treatment beyond documented RECIST 1.1 or disease progression. Subjects&#xD;
      who are both CPI (checkpoint inhibitor) na√Øve as well as subjects who have received or&#xD;
      progressed following a CPI will be eligible and include the following tumor types: head and&#xD;
      neck squamous cell carcinoma (HNSCC), cervical carcinoma, gastric or gastroesophageal&#xD;
      carcinoma, endometrial carcinoma, tumor mutation burden high (TMB-H), select rare tumors and&#xD;
      ovarian carcinoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Basket study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Approximately 24 months.</time_frame>
    <description>The ORR is the proportion of subjects whose best response rate (BOR) is confirmed CR or confirmed PR radiographically according to RECISTv1.1. Where BOR is defined as the best investigator-assessed confirmed response during the time period.</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <condition>Advanced Solid Tumor</condition>
  <condition>Metastatic Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Squamous cell carcinoma of the head and neck</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advanced and/or recurrent or metastatic squamous cell carcinoma of the head and neck</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cervical cancer on or after chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gastric or gastroesophageal junction adenocarcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endometrial carcinoma post-platinum &lt;3L treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advanced and/or metastatic endometrial carcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tumor burden high (TMB-H) and microsatellite stable (MSS) solid tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advanced or metastatic tumor mutational burden-high (TMB-H)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rare disease with high prevalence of TIGIT expression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Select rare tumors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ovarian cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recurrent high grade serous and endometrioid ovarian cancer, fallopian tube cancer or primary peritoneal cancer following front-line platinum-based therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endometrial carcinoma post standard of care therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advanced and/or metastatic endometrial carcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etigilimab dosing</intervention_name>
    <description>IV infusion of IV etigilimab every 2 weeks</description>
    <arm_group_label>Cervical cancer on or after chemotherapy</arm_group_label>
    <arm_group_label>Endometrial carcinoma post standard of care therapy</arm_group_label>
    <arm_group_label>Endometrial carcinoma post-platinum &lt;3L treatment</arm_group_label>
    <arm_group_label>Gastric or gastroesophageal junction adenocarcinoma</arm_group_label>
    <arm_group_label>Ovarian cancer</arm_group_label>
    <arm_group_label>Rare disease with high prevalence of TIGIT expression</arm_group_label>
    <arm_group_label>Squamous cell carcinoma of the head and neck</arm_group_label>
    <arm_group_label>Tumor burden high (TMB-H) and microsatellite stable (MSS) solid tumors</arm_group_label>
    <other_name>MPH313</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>IV infusion of nivolumab every 2 weeks</description>
    <arm_group_label>Cervical cancer on or after chemotherapy</arm_group_label>
    <arm_group_label>Endometrial carcinoma post standard of care therapy</arm_group_label>
    <arm_group_label>Endometrial carcinoma post-platinum &lt;3L treatment</arm_group_label>
    <arm_group_label>Gastric or gastroesophageal junction adenocarcinoma</arm_group_label>
    <arm_group_label>Ovarian cancer</arm_group_label>
    <arm_group_label>Rare disease with high prevalence of TIGIT expression</arm_group_label>
    <arm_group_label>Squamous cell carcinoma of the head and neck</arm_group_label>
    <arm_group_label>Tumor burden high (TMB-H) and microsatellite stable (MSS) solid tumors</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological diagnosis of a relevant tumor type as per the study&#xD;
             protocol and not candidates for curative surgery or radiation therapy&#xD;
&#xD;
          -  Available tumor tissue (archival or newly obtained core or excisional biopsy)&#xD;
&#xD;
          -  Adequate hematologic and end organ function as measured by laboratory screening panel&#xD;
             in the 14 days prior to treatment&#xD;
&#xD;
          -  Life expectancy greater than 12 weeks.&#xD;
&#xD;
          -  ECOG performance status of 0 to 1&#xD;
&#xD;
          -  Adequate contraception for women of childbearing potential&#xD;
&#xD;
          -  Pre-specified wash-out of prior anti-PD1/PDL-1 therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent active malignancy&#xD;
&#xD;
          -  Major surgery within 4 weeks of treatment&#xD;
&#xD;
          -  Subjects with active, known or suspected autoimmune diseases&#xD;
&#xD;
          -  Prior treatment with CD137 agonists, anti-CTLA-4 and anti-TIGIT antibodies&#xD;
&#xD;
          -  History of any Grade 3 or 4 immune-related AE toxicity from prior immunotherapy that&#xD;
             resulted in treatment discontinuation&#xD;
&#xD;
          -  History of immune-related adverse events that lead to discontinuation of anti-PD-1 or&#xD;
             PDL-1 therapy&#xD;
&#xD;
          -  Active infections of HIV, hepatitis B, hepatitis C&#xD;
&#xD;
          -  Medical illness or abnormal laboratory finding that would, in the Study Investigator's&#xD;
             judgement, increase the risk to the subject associated with participation in the study&#xD;
&#xD;
          -  Pregnancy in female subjects&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>James Clancy</last_name>
    <phone>1 650 995 8200</phone>
    <email>enquiries@mereobiopharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suba Krishnan, M.D.</last_name>
    <phone>1 650 995 8200</phone>
    <email>enquiries@mereobiopharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Clancy</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Clancy</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Clancy</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Clancy</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Clancy</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Clancy</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Clancy</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Clancy</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Clancy</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Clancy</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Clancy</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Clancy</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>West Valley City</city>
        <state>Utah</state>
        <zip>84119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Clancy</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mereo Investigator Site</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Clancy</last_name>
      <email>enquiries@mereobiopharma.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>etigilimab</keyword>
  <keyword>nivolumab</keyword>
  <keyword>anti-TIGIT antibody</keyword>
  <keyword>MPH313</keyword>
  <keyword>Opdivo</keyword>
  <keyword>ACTIVATE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

